Skip to main navigation Skip to search Skip to main content

GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction

  • University of Florida College of Medicine
  • University of Florida
  • Shenzhen Geno-Immune Medical Institute
  • Siriraj Hospital
  • University of Electronic Science and Technology of China

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Abstract

A novel disialoganglioside 2 (GD2)-specific chimeric antigen receptor (CAR)-modified T cell therapy against retinoblastoma (RB) were generated. GD2-CAR consists of a single-chain variable fragment (scFv) derived from a monoclonal antibody, hu3F8, that is linked with the cytoplasmic signaling domains of CD28, 41BB, a CD3ζ, and an inducible caspase 9 death fusion partner. GD2 antigen is highly expressed in Y79RB cell line and in several surgical RB tumor specimens. In vitro co-culture experiments revealed the effective killing of Y79RB cells by GD2-CAR T cells, but not by control CD19-CAR T cells. The killing activities of GD2-CAR T cells were diminished when repeatedly exposed to the tumor, due to an attenuated expression of GD2 antigen on tumor cells and upregulation of inhibitory molecules of the PD1 and PD-L1 axis in the CAR T cells and RB tumor cells respectively. This is the first report to describe the potential of GD2-CAR T cells as a promising therapeutic strategy for RB with the indication of potential benefit of combination therapy with immune checkpoint inhibitors.

Original languageEnglish
Article number100971
JournalTranslational Oncology
Volume14
Issue number2
DOIs
Publication statusPublished - Feb 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Chimeric antigen receptor T cells
  • Disialoganglioside 2
  • GD2
  • Retinoblastoma

Fingerprint

Dive into the research topics of 'GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction'. Together they form a unique fingerprint.

Cite this